..regarding the science based evidence that has been amasssed over the past two years, I for one feel very confident in the design of the upcoming Parkinsons and Fragile X trials, and for that fact all future plans for such. Missling sure has been raked over the coals for the mistakes of the past here. His comment in early '25 regarding the trial delays was that you had to have the correct design for success. The findings and deeper understanding of the science emphasizes this paradigm shift as a new approach to treating CNS disease. There has been a strong positive learning curve here over this time. Given FDA guidelines for Alzheimers have also changed, Anavex sure looks like it is finally in the right place at the right time...
Market Data 
Markets 
AI
